ampelopsin has been researched along with erlotinib hydrochloride in 1 studies
| Studies (ampelopsin) | Trials (ampelopsin) | Recent Studies (post-2010) (ampelopsin) | Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) |
|---|---|---|---|---|---|
| 377 | 2 | 343 | 4,353 | 786 | 3,033 |
| Protein | Taxonomy | ampelopsin (IC50) | erlotinib hydrochloride (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1683 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 1.705 | |
| Serine/threonine-protein kinase B-raf | Mus musculus (house mouse) | 0.04 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, BN; Hong, SW; Hur, DY; Kim, D; Kim, YS; Lee, HK; Noh, MH; Park, NS; Shim, JA | 1 |
1 other study(ies) available for ampelopsin and erlotinib hydrochloride
| Article | Year |
|---|---|
Combination treatment with erlotinib and ampelopsin overcomes erlotinib resistance in NSCLC cells via the Nox2-ROS-Bim pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Humans; Lung Neoplasms; Mutation; NADPH Oxidase 2; Protein Kinase Inhibitors; Reactive Oxygen Species; RNA, Small Interfering | 2017 |